ACXP Acurx Pharmaceuticals, Inc.
USHealthcareAs of 2026-07-10 16:00
Why ACXP matters now
Acurx Pharmaceuticals, Inc. (ACXP) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.50 with +2.74% on the session and $2.4M in market capitalization; recent performance reads 1-month -18.09% and YTD -38.15%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-1.7M, and EPS of $-1.12. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -251.7%.
The latest indexable market news headline is "Axos Aims to Expand AI-Powered Financial Services With Arc Acquisition" from PYMNTS.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—; recent insider activity includes Shawah Robert G. filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.33
P/S
0.00
EV/EBITDA
0.91
DCF Value
$5,040.79
FCF Yield
-251.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-153.9%
ROA
-78.6%
ROIC
-108.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-1.7M | $-1.12 |
| Q4 2025 | $0.00 | $-1.6M | $-0.67 |
| FY 2025 | $0.00 | $-8.0M | $-5.32 |
| Q3 2025 | $0.00 | $-2.0M | $-1.23 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
-2.09
Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections. The company's primary drug candidate is ibezapolstat, an antibiotic that utilizes a novel mechanism of action by targeting the polymerase IIIC enzyme. Ibezapolstat has successfully completed Phase II clinical trials for addressing Clostridium difficile infections. Additionally, Acurx is progressing with ACX-375C, an investigational therapeutic suitable for both oral and injectable administration. This compound is being developed to combat various gram-positive bacteria, including resistant strains such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and penicillin-resistant Streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was established in 2017 and is headquartered in Staten Island, New York.